Sage Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sage Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sage Therapeutics Inc Strategy Report
- Understand Sage Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of central nervous system (CNS) disorders. The company’s product portfolio encompasses candidates that focus on modulating two vital CNS receptor systems, namely, GABA and NMDA. The GABA receptor family is the major inhibitory neurotransmitter in the CNS that mediates downstream neurological and bodily functions through the activation of GABA A receptors.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The R&D efforts of Sage focus on the allosteric modulation of the GABA A and NMDA receptor systems in the brain. The company is advancing a portfolio of clinical programs consisting of internally- discovered new chemical entities that have the potential to become differentiated products that will improve brain health by targeting the GABA A and NMDA receptor systems. The company’s R&D activities are focused therapy areas such as central nervous system (CNS), Dementia, Epilepsy, Parkinson’s Disease, Postpartum Depression and Major Depressive Disorder. Sage is testing SAGE-718 in neurodegenerative disorders such as Huntington's, Alzheimer's, and Parkinson's. In FY2022, the company spent US$326.2 million on its R&D activities. In FY2022, it spent US$93.4 million on the development of SAGE-217; US$31.5 million on SAGE-324 and US$45.8 million on SAGE-718.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer